Skip to main content
Premium Trial:

Request an Annual Quote

Progenika Licenses Protein Array Tech from Harvard Spin-out Auguron

NEW YORK (GenomeWeb News) –Harvard University spin-out company Auguron Biosciences has licensed its Nucleic Acid Programmable Protein Array (NAPPA) technology to Proteomika, a subsidiary of Progenika Biopharma.
 
Under the agreement, Proteomika may use the NAPPA technology at its facilities for in its autoimmune research and service programs, and it may exercise an option to negotiate an exclusive license to NAPPA within the field of biomarker discovery for inflammatory bowel disease and lupus.
 
Proteomika CEO Laureano Simon said that lupus and IBD sufferers “need better biomarkers for diagnosis, prognosis, and drug response,” and that the NAPPA technology will provide it with multiplex technology to discover antibodies that can be applied to both diseases.
 
Auguron was started in early 2007 as a commercialization arm for the Harvard Institute for Proteomics.
 
Financial terms of the agreement were not released.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.